Can Protein Intake be Increased Using Whole Foods Post-treatment in Cancer Patients?
NCT ID: NCT05859100
Last Updated: 2025-11-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
2 participants
INTERVENTIONAL
2023-09-01
2025-06-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
the Safety and Effectiveness of Protein Supplements on Cancer Patients With Nutritional Risk and Malnutrition
NCT05802381
Influence of an Oral Nutritional Supplement Rich in Omega-3 Fatty Acids on Functional State and Quality of Life in Malnourished Patients With Gastroenterological Tumors
NCT00168987
Nutritional Supplementation in Patients With no Signs of Malnutrition
NCT01894828
Nutrition Intervention During Chemotherapy
NCT01871350
The Effect of Soy Protein on Post- Breast Cancer Surgery Pain
NCT01047774
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
SUPPORTIVE_CARE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Early Intervention
Participants are expected to begin intervention immediately after the completion of treatment for a period of 8 weeks.
≥ 2 eggs in addition to usual diet for 8 weeks
Participants are expected to consume≥ 2 eggs per day in addition to usual diet for 8 weeks in early intervention arm, beginning immediately post-treatment.
Delayed Intervention
Participants are expected to begin intervention 4 weeks after the completion of the treatment, for a period of 4 weeks (weeks 5-8).
≥ 2 eggs in addition to usual diet for 4 weeks
Participants are expected to continue intake of regular diet beginning immediately at post-treatment recovery for a duration of 4 weeks, then crossover to nutritional intervention arm from weeks 5 to 8 of post-treatment recovery for a duration of 4 weeks.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
≥ 2 eggs in addition to usual diet for 8 weeks
Participants are expected to consume≥ 2 eggs per day in addition to usual diet for 8 weeks in early intervention arm, beginning immediately post-treatment.
≥ 2 eggs in addition to usual diet for 4 weeks
Participants are expected to continue intake of regular diet beginning immediately at post-treatment recovery for a duration of 4 weeks, then crossover to nutritional intervention arm from weeks 5 to 8 of post-treatment recovery for a duration of 4 weeks.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* ≥18 years of age
* Histopathologically confirmed cancer with receipt of a platinum chemotherapy during treatment; active treatment has concluded.
* Capable of volitional oral semi-solid intake at baseline; able to maintain oral intake over the trial.
Exclusion Criteria
* Cancer of the brain, Cancer of the regions which impact an individual's ability to consume food.
* A known hypersensitivity / allergy to eggs.
* Enrolment in any other clinical protocol or investigational study that may interfere with study procedures.
* Poorly controlled chronic illnesses or other inflammatory diseases (e.g. Chronic Obstructive Pulmonary Disease(COPD), uncontrolled non-insulin dependent diabetes, rheumatoid arthritis).
* In a clinician opinion, patients who have medical conditions that could interfere with nutrient metabolism or absorption (e.g., short bowel syndrome, Crohn's disease, etc.)
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Egg Farmers of Canada
UNKNOWN
University of Alberta
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Vera Mazurak, PhD
Role: PRINCIPAL_INVESTIGATOR
University of Alberta
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Alberta
Edmonton, Alberta, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HREBA.CC-22-0348
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.